为期12周的地中海型限时进食方案对代谢功能障碍相关脂肪性肝病患者的效应:一项随机对照试验——CHRONO-NAFLD项目
三组体重、人体测量指标和血压均显著下降,仅早期限时进食组在12周时糖化血红蛋白A1c和胰岛素抵抗指标改善。
要点
- 三组12周体重、人体测量指标和血压均显著下降。
- 早期限时进食组12周时糖化血红蛋白A1c和胰岛素抵抗指标改善。
- 晚期限时进食组未报告血糖控制指标的改善。
核心结论
- 本研究证实地中海饮食可改善代谢功能障碍相关脂肪性肝病患者的体重和血压等心脏代谢危险因素。
- 与早期限时进食方案联合可能改善血糖控制(NCT05866744)。
研究设计与样本
- 为期12周的随机对照试验,纳入59例超重或肥胖的代谢功能障碍相关脂肪性肝病患者(男性27例;年龄52.9岁;体重指数32.1 kg/m2)。
- 通过食物日记追踪依从性,干预后进行8周随访。
主要发现
- 完成试验者共59例:对照组19例,早期限时进食组20例,晚期限时进食组20例。
- 三组在12周时体重、人体测量指标和血压均显著下降。
- 早期限时进食组在12周时糖化血红蛋白A1c及以Matsuda指数、稳态模型评估胰岛素抵抗指数和空腹血糖胰岛素比值衡量的胰岛素抵抗改善。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Mediterranean diet (MD) is considered the best dietary approach for patients with metabolic dysfunction-associated steatotic liver disease (MASLD). Recently, time-restricted feeding (TRF) has gained attention for its lifestyle compatibility and health benefits. AIMS: This study aimed to compare the effects of a hypocaloric MD with a 10-h TRF protocol to an unrestricted MD in MASLD patients with overweight/obesity and evaluate differences between early and late TRF. METHODS: This 12-week randomised controlled trial in MASLD patients with overweight/obesity consisted of three groups, all following a hypocaloric Mediterranean-type diet. The control group had no eating time restrictions. The early TRF (eTRF) and late TRF (lTRF) groups had a 10-h eating window, from 8 AM to 6 PM and from 12 PM to 10 PM, respectively. Various health parameters were measured. Compliance was tracked via food diaries, and an 8-week follow-up occurred post-intervention. RESULTS: Fifty-nine MASLD individuals (27 males; 52.9 years; body mass index 32.1 kg/m2) completed the trial (control, n = 19; eTRF, n = 20; lTRF, n = 20). All groups showed significant 12-week reductions in body weight, anthropometry and blood pressure. Glycated haemoglobin A1c and insulin resistance, as measured by the Matsuda index, homeostatic model assessment for insulin resistance and fasting glucose-to-insulin ratio, improved in the eTRF group at 12 weeks. CONCLUSIONS: This study corroborates the efficacy of MD in ameliorating cardiometabolic risk factors such as body weight and blood pressure in MASLD patients. The combination with an eTRF protocol may improve glycaemic control (NCT05866744). TRIAL REGISTRATION: The study is registered at clinicaltrials.gov (NCT05866744).
引用
- Tsitsou S, Bali T, Adamantou M, et al. Effects of a 12-Week Mediterranean-Type Time-Restricted Feeding Protocol in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Randomised Controlled Trial-The 'CHRONO-NAFLD Project'. Aliment Pharmacol Ther. 2025. PMID: 40017349. doi:10.1111/apt.70044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。